Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Through clinical trials, investigators find that SGLT2 inhibitors are not only safe, but have several cardiovascular benefits.
Clinical trials have long shown that SGLT2 inhibitors have a number of positive cardiovascular benefits for patients.
In an interview with MD Magazine® during the 2nd Annual Advanced Practice Collaborative on September 7, Scott Urquhart, PA-C, adjunct clinical professor at the James Madison University PA program explained some of the benefits of the drug, as well as how reducing cardiovascular disease plays a role in diabetes.
MD Mag: SGLT2 inhibitors are a hot topic for diabetics and non-diabetics. How exciting is it to see these agents have an impact on improving cardiovascular health in major trials?
Urquhart: Lots of changes have really occurred in the time with diabetes and I've been practicing since 1996 and as we see this evolution and time and kind of what we've done now with these newer trials, cardiovascular trials. They evolved from 2007 when there was a meta-analysis done thinking that one of the agents TZD class was actually a cause for increased risk of cardiovascular events and as a result FDA stepped in and designed ways in which were to further investigate the safety of all new drugs coming to the market from 2008 and onward.
And looking at the safety of these drugs we find they're safe but then we stumbled across or kind of they predicted in the trials that there might be some cardiovascular benefits associated with them. So, in addition to other classes, the SGLT2 inhibitor class has been very exciting and seeing improvements in cardiovascular outcomes particularly that in heart failure. But also the real exciting part now that we're seeing is the benefits also in in kidney function preserving kidney function delaying onset for end-stage renal disease and protecting from microbial malaria and so forth. So, lots of benefits on the kidney in the heart and we know that there the kidney in the harder are intertwined together working together as is very unique systems.
MD Mag: How much of a role does cardiovascular risk reduction play in diabetes management right now and how much of a role should it play ideally?
Urquhart: That's a great question because I think when we look at our patient populations right now. So, I'm an endocrinology and we see a lot more patients in my practice cardiovascular disease then perhaps people in primary care settings where they may be seeing more healthy patients with less chronic conditions. So, in their practice setting they may be seeing 15% of the population, 20% of population has cardiovascular disease with their type 2 diabetes. In my practice setting it could be as high as 40 or 50% and then of course cardiology it's nearly 100%.
So, it does really lead us into a different direction so the usual screening for me when I was treating patients with medications is what was my a1c target was my glucose target was I going for. Now I have to kind of look deeper into the patient do they have chronic kidney disease you know are they having a history of heart failure do they have cardiovascular disease and that really changes the way in which I treat him. Well in my lecture we'll see only ADA 2019 guidelines it talks about patients that have diabetes without cardiovascular disease and those that have cardiovascular disease and kidney disease and it kind of gives you 2 different algorithms to work through to make those decisions. But absolutely the 1 thing I think we need to keep in mind is just because the patients have been identified with having cardiovascular disease doesn't mean there's a large portion out there lurking with early cardiovascular disease that has not been identified yet.